Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 10;6(1):228.
doi: 10.1038/s41392-021-00654-9.

The paradox of immunotherapy in NASH-HCC

Yao Peng  1   2 , Chi Chun Wong  2 , Jun Yu  3   4
Affiliations
Comment

The paradox of immunotherapy in NASH-HCC

Yao Peng et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Anti-PD1 immunotherapy promotes NALFD-associated HCC. sc-RNA seq analysis of NAFLD/NASH patients identified the hepatic-resident-like and exhausted CD8+PD1+ T cells. Mechanistic studies in animal models reveal progressive accumulation of unconventionally activated CD8+PD1+ T cells in the NASH liver, and anti-PD1 treatment promotes CD8+PD1+ T cells population and stimulates them to generate TNF-α, leading to increased inflammation, fibrosis, and tumorigenesis. Survival analysis in HCC patients shows worse outcome in NAFLD-HCC patients receiving anti-PD1 immunotherapy
See this image and copyright information in PMC

Comment on

  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet… See abstract for full author list ➔ Pfister D, et al. Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. Nature. 2021. PMID: 33762733 Free PMC article.

References

    1. Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature592, 450–456 (2021). - PMC - PubMed
    1. Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7:113–123. doi: 10.1001/jamaoncol.2020.3381. - DOI - PMC - PubMed
    1. Ringelhan M, et al. The immunology of hepatocellular carcinoma. Nat. Immunol. 2018;19:222–232. doi: 10.1038/s41590-018-0044-z. - DOI - PubMed
    1. Dudek, M. et al. Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. Nature592, 444–449 (2021). - PubMed
    1. Finn RS, et al. IMbrave150: updated overall survival data from a global, randomized, open-label phase III study of atezolizumab+ bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 2021;39:abstr 267. doi: 10.1200/JCO.2021.39.3_suppl.267. - DOI

Publication types